HCV Protease

信号通路图

研究领域

  • 抑制剂选择性比较
  • 溶解性比较
目录号 产品目录 溶解度(25°C)
DMSO 酒精
S1482 Daclatasvir (BMS-790052) <1 mg/mL 148 mg/mL 148 mg/mL
S1538 Telaprevir (VX-950) <1 mg/mL 136 mg/mL <1 mg/mL
S1480 Lomibuvir (VX-222, VCH-222) <1 mg/mL 89 mg/mL 89 mg/mL
S1183 Danoprevir (ITMN-191) <1 mg/mL 144 mg/mL 144 mg/mL
S4935 Asunaprevir <1 mg/mL 100 mg/mL 100 mg/mL
S5652 Elbasvir <1 mg/mL 100 mg/mL 100 mg/mL
S5394 Tizoxanide <1 mg/mL 27 mg/mL <1 mg/mL
S5402 Dasabuvir(ABT-333) <1 mg/mL 98 mg/mL <1 mg/mL
S5404 Paritaprevir (ABT-450) -1 mg/mL 100 mg/mL -1 mg/mL
S5403 Ombitasvir (ABT-267) -1 mg/mL 100 mg/mL -1 mg/mL
S5307 PSI-6206 (RO-2433, GS-331007) 52 mg/mL 52 mg/mL 24 mg/mL
S5062 Daclatasvir Digydrochloride 100 mg/mL 100 mg/mL 100 mg/mL
S5015 Simeprevir <1 mg/mL 100 mg/mL 4 mg/mL
S3800 Lycorine hydrochloride -1 mg/mL 64 mg/mL -1 mg/mL
S3728 Grazoprevir <1 mg/mL 100 mg/mL 100 mg/mL
S7579 Ledipasvir (GS5885) <1 mg/mL 100 mg/mL 100 mg/mL
S3724 Velpatasvir 100 mg/mL 100 mg/mL 100 mg/mL
S3733 Boceprevir <1 mg/mL 100 mg/mL 100 mg/mL
产品目录 产品描述 文献引用 实验数据
S1482

Daclatasvir (BMS-790052)

Daclatasvir (BMS-790052)是一种高度选择性的HCV NS5A抑制剂,EC50为9-50 pM,在细胞培养中,作用于多种HCV复制基因型和JFH-1基因型2a的感染性病毒。Phase 3。

S1538

Telaprevir (VX-950)

Telaprevir (VX-950)是一种丙型肝炎病毒(HCV)NS3-4A丝氨酸蛋白酶抑制剂,IC50为0.354 μM。

S1480

Lomibuvir (VX-222, VCH-222)

Lomibuvir (VX-222, VCH-222)是一种新型的,有效的,选择性的HCV聚合酶抑制剂,IC50为0.94-1.2 μM,作用于突变型M423T效果低15.3倍,作用于突变型I482L效果低108倍。Phase 2。

S1183

Danoprevir (ITMN-191)

Danoprevir (ITMN-191)是一种肽类抑制剂,作用于丙型肝炎病毒(HCV)的NS3/4A蛋白酶IC50为0.2-3.5 nM,抑制HCV 1A/1B/4/5/6基因型比抑制2B/3A基因型效果高10倍左右。Phase 2。

S4935New

Asunaprevir

Asunaprevir是具有口服活性的HCV NS3抑制剂。HCV NS3是病毒复制蛋白加工所必需的蛋白酶。

S5720New

Glecaprevir

Glecaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that targets the the viral RNA replication. It displays IC50 values ranging from 3.5 to 11.3 nM for clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a.

S5652New

Elbasvir

Elbasvir is an NS5A inhibitor, preventing hepatitis C viral RNA replication and virion assembly. Median EC50 values range from 0.2 to 3600 pmol/L, based on genotype.

S5394New

Tizoxanide

Tizoxanide, a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C.

S5402New

Dasabuvir(ABT-333)

Dasabuvir(ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases.

S5404New

Paritaprevir (ABT-450)

Paritaprevir (ABT-450)是NS3/4A抑制剂。

S5403New

Ombitasvir (ABT-267)

Ombitasvir (ABT-267)是HCV NS5A的抑制剂,具有抗病毒活性。

S5307New

PSI-6206 (RO-2433, GS-331007)

PSI-6206 (RO-2433, GS-331007)是有效的HCV RNA依赖性RNA聚合酶抑制剂,靶向NS5B聚合酶

S5062New

Daclatasvir Digydrochloride

Daclatasvir是一种具有口服活性的抗病毒剂,抑制HCVNS5A区域,用于治疗慢性遗传型1和3类的HCV感染。

S5015New

Simeprevir

Simeprevir一种竞争性的、可逆的、非共价结合的大环hepatitis C virus (HCV) NS3/4A protease抑制剂,直接抑制HCV病毒。它对HCV NS3/4A(genotypes 1a, 1b, 2, 4, 5, and 6)的平均IC50值小于13 nM,而对genotype 3的IC50值为37 nM。

S3800New

Lycorine hydrochloride

Lycorine, a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit a wide range of physiological effects, including the potential effect against cancer. It is an HCV inhibitor with strong activity.

S3728

Grazoprevir

Grazoprevir anhydrous is a Hepatitis C Virus NS3/4A Protease inhibitor with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively.

S7579

Ledipasvir (GS5885)

Ledipasvir(GS5885)是一种HCV NS5A polymerase抑制剂,用于治疗丙型肝炎病毒感染。

S3724

Velpatasvir

Velpatasvir是二代NS5A抑制剂,抑制丙型肝炎病毒(HCV)的复制。

S3733

Boceprevir

Boceprevir是一种口服的、直接作用于hepatitis C virus (HCV) protease的抑制剂,对NS3蛋白酶的Ki值为14 nM。在治疗慢性肝炎C(genotype 1)中,常与其他抗病毒共同给药。

Tags: HCV protease treatment | HCV protease assay | HCV protease inhibitors review